Table 2.
Summary of base case analysis results
| Cladribine tablets | Natalizumab | |
|---|---|---|
| Total Discounted | ||
| Cost (USD) | 69.842 | 76.449 |
| LYG | 4.655 | 4.655 |
| QALY | 2.720 | 2.716 |
| Inc. (Cladribine Tablets vs. Natalizumab) | ||
| Inc. Cost (USD) | - | -6.606 |
| Inc. LYG | - | 0.000 |
| Inc. QALY | - | 0.003 |
| ICER vs Cladribine (QALY) | - | Cladribine tablets are dominant |
ICER: Incremental cost effectiveness ratio; Inc.: Incremental; LYG: Life years gained; QALY: Quality adjusted life years; USD: United States Dollar